The DEXLIFE study methods: identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      DEXLIFE Consortium
    • Source:
      Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE
    • Publication Information:
      Publication: 1993- : Limerick : Elsevier Scientific Publishers
      Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985-
    • Subject Terms:
      Biomarkers/*analysis ; Diabetes Mellitus, Type 2/*diagnosis ; Glucose Intolerance/*diagnosis ; Glucose Intolerance/*pathology ; Prediabetic State/*diagnosis ; Prediabetic State/*pathology; Adult ; Aged ; Case-Control Studies ; Cohort Studies ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/prevention & control ; Diet Therapy ; Disease Progression ; Exercise Therapy ; Female ; Glucose Intolerance/epidemiology ; Glucose Intolerance/therapy ; Humans ; Life Style ; Male ; Middle Aged ; Prediabetic State/epidemiology ; Prediabetic State/therapy ; Prognosis ; Risk Factors ; Risk Reduction Behavior ; Young Adult
    • Abstract:
      The incidence of type 2 diabetes (T2D) is rapidly increasing worldwide and T2D is likely to affect 592 million people in 2035 if the current rate of progression is continued. Today, patients are diagnosed with T2D based on elevated blood glucose, either directly or indirectly (HbA1c). However, the information on disease progression is limited. Therefore, there is a need to identify novel early markers of glucose intolerance that reflect the underlying biology and the overall physiological, metabolic and clinical characteristics of progression towards diabetes. In the DEXLIFE study, several clinical cohorts provide the basis for a series of clinical, physiological and mechanistic investigations in combination with a range of--omic technologies to construct a detailed metabolic profile of high-risk individuals across multiple cohorts. In addition, an exercise and dietary intervention study is conducted, that will assess the impact on both plasma biomarkers and specific functional tissue-based markers. The DEXLIFE study will provide novel diagnostic and predictive biomarkers which may not only effectively detect the progression towards diabetes in high risk individuals but also predict responsiveness to lifestyle interventions known to be effective in the prevention of diabetes.
      (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
    • Contributed Indexing:
      Investigator: G O'Donoghue; A Kennedy; N McCaffrey; S Cleary; H Kenny; E Durkin; P O'Connor; J Monedero; L Breen; M Laakso; L Yetukuri; M Sysi-Aho; M Berdasco; MI Hernandez-Alvarez; MA Diaz-Ramos; M Sinnott; B Kinsley; K Pappan; K Nilsson
      Keywords: Biomarkers; Lifestyle intervention; Prevention; Type 2 diabetes
    • Molecular Sequence:
      ISRCTN ISRCTN66987085
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20140816 Date Completed: 20150707 Latest Revision: 20181202
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.diabres.2014.07.025
    • Accession Number:
      25125339